Soleno Therapeutics Inc (SLNO, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics Inc has a market cap of $72.402 million; its shares were traded at around $2.28 . Soleno Therapeutics Inc had annual average EBITDA growth of 35.20% over the past five years.
At the end of the fiscal year, Soleno Therapeutics Inc has the cash and cash equivalents of $23.1 million, compared with $17.1 million in the previous year. The company had no long term debt. Soleno Therapeutics Inc has a financial strength rank of 5 (out of 10).
Directors and Officers Recent Trades:
- 10% Owner Larry N Feinberg bought 130,363 shares of SLNO stock on 03/14/2019 at the average price of $1.22. The price of the stock has increased by 86.89% since.
For the complete 20-year historical financial data of SLNO, click here.
